Tagged with IPO

France When Marc de Garidel joined AbiVax as CEO in 2023, the firm had very recently teetered on the brink of bankruptcy. Now, less than three short years later, he leads the hottest prospect in European biotech, with a potentially market-leading drug for inflammatory bowel disease nearing regulatory approval. de Garidel…

Taiwan Lih-Chung Chien, Chairman of the Taipei Exchange (TPEx), highlights the Exchange’s support for SMEs and innovative sectors via a three-tiered market, flexible IPO rules, and the Technology-Based Enterprise mechanism. Taiwan’s strong clusters in biotech, ICT, and semiconductors, along with supportive policies and active investor participation, make it a compelling destination…

Hong Kong After a challenging few years, the Hong Kong Stock Exchange (HKEX)’s IPO market bounced back strongly in 2025. By the end of Q3 2025, HK listings raised USD 23.9 billion across 66 IPOs (up 192 percent vs the previous year). Pre-revenue biotech listings, predominantly from mainland China, are also up…

USA As the world’s largest stock exchange, the New York Stock Exchange (NYSE) plays a pivotal role in shaping access to capital for healthcare and life sciences companies. Johanna Grossman, PhD, who leads this sector for the NYSE, reflects on her career path, the exchange’s growing footprint in biotech, and the…

China 3D Medicines has charted a deliberate path from domestic clinical execution to global oncology innovation. Since its IPO, the company has sharpened its focus on differentiated assets like Envafolimab, while expanding into radioligand and mRNA-based platforms with broad therapeutic potential. Chairman and CEO Dr John Gong outlines how strategic discipline,…

USA The latest stories from healthcare and the life sciences in the US. RFK Jr shares his 128 recommendations for addressing childhood chronic disease; Suspension of Capsida’s gene therapy clinical trial after patient death; Courts half another attempt to challenge the IRA’s negation program; Takeda scoops up former Lilly exec to…

China Jiangsu Hengrui Pharmaceuticals is no longer just a local biopharma heavyweight. With a record-breaking and 450x oversubscribed IPO raising USD 1.27 billion, a flurry of global licensing deals with the likes of Merck and GSK, and a bold push into competitive therapeutic areas like obesity, the company is staking its…

Denmark Once a quiet legacy player in dermatology, LEO Pharma is re-emerging with renewed focus and ambition under CEO Christophe Bourdon. With global leadership experience at Amgen and Alexion, Bourdon is guiding the century-old company through a bold transformation, restoring profitability, embracing external innovation, and laying the groundwork for a potential…

Global Originally seen as occasional service providers for the pharma industry, contract development and manufacturing organisations (CDMOs) have become vital strategic partners. Helping pharma and biotech companies advance their therapies through their outsourced services, CDMOs have demonstrated their ability to respond to the industry’s shifting priorities as well as its pre-…

Hong Kong After the Hong Kong Exchanges and Clearing Limited’s (HKEX) 2018 move to allow pre-revenue biotech companies to raise capital in Hong Kong under its Chapter 18A mechanism, biotech listings surged with pre-clinical companies chosing to list on HKEX as a means of accessing global capital, raising around HKD 118 billion…

China Established in 2017 as a spin-off from Lee’s Pharmaceutical, Zhaoke Ophthalmology is aiming to be a global player in the ophthalmology field, building on its strong footprint in China and Asia to eventually establish operations in the US and Europe. President and Chief Scientific Officer Lau Lit Fui outlines how…

Taiwan In just 35 years, Taiwan has gone from having no biotechs on the TAIEX and Taiwan OTC stock exchanges to 124 listed firms with a combined market capitalization of more than USD 30 billion by 2020, as the below chart from the Carnegie Endowment for International Peace shows. In 2019,…